Navigation Links
Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
Date:7/30/2013

THOUSAND OAKS, Calif., July 30, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2013.  Key results for the quarter include:

  • Total revenues increased 5 percent to $4,679 million, with 9 percent product sales growth driven by Enbrel® (etanercept), Neulasta® (pegfilgrastim), XGEVA® (denosumab), and Prolia® (denosumab).  Product sales included a positive adjustment of $185 million to previous estimates for managed Medicaid rebates based on recent claims experience.  Other revenues were lower by $193 million as a result of a payment from Takeda recognized in the second quarter of 2012.
  • Adjusted EPS grew 3 percent to $1.89, with higher revenues and a lower tax rate partially offset by increased Research & Development (R&D) investment.  Adjusted net income increased 1 percent to $1,444 million.
  • GAAP EPS were $1.65 compared to $1.61 and GAAP net income was $1,258 million compared to $1,266 million.
  • The Company generated approximately $1.4 billion of free cash flow.
  • "We saw solid product trends during the second quarter and are carrying good momentum into the second half," said Robert A. Bradway, chairman and chief executive officer at Amgen. "We continue to make excellent progress with our pipeline of innovative molecules and look forward to multiple data readouts in 2014, including pivotal Phase 3 data for our cholesterol-lowering agent, AMG 145, in the first quarter."Year-over-Year$Millions, except EPS and percentagesQ2 '13Q2 '12YOY ΔTotal Revenues$4,679$4,4775%Adjusted Net Income1,4441,4331%Adjusted EPS1.891.833%GAAP Net Income1,2581,266(1%)GAAP EPS$1.65$1.612%References in this release to "adjusted" measures, measures presented "on an adjusted basis" or to free cash flow refer
    '/>"/>

    SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
    2. Oncology remains most restrictive specialty for second year
    3. China Biologic Products to Report Second Quarter 2013 Financial Results
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
    5. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
    6. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
    7. VirtualScopics Schedules Second Quarter 2013 Earnings Announcement
    8. Luminex Corporation Reports Second Quarter 2013 Results
    9. Endo to Announce Second Quarter 2013 Financial Results on August 6, 2013
    10. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
    11. PDI, Inc. to Hold Second Quarter 2013 Financial Results Conference Call on Monday, August 5, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
    (Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
    (Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
    Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
    ... Jan. 31, 2012 Halozyme Therapeutics, Inc. (NASDAQ: ... Phase 1 proof-of-concept and local tolerability study of HTI-501 ... 8th World Congress of the International Academy of Cosmetic ... commencement of the Phase 2 portion of the clinical ...
    ... LAKES, N.J., Jan. 31, 2012 The Board of Directors of ... declared a quarterly dividend of 45 cents per common share, payable ... 2012. The indicated annual dividend rate is $1.80 per share. ... is a leading global medical technology company that develops, manufactures and ...
    Cached Medicine Technology:HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 2HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 3
    (Date:9/30/2014)... [Brown University] Autism is no stranger to the ... African nation is access to clinical services, including reliable ... measure, for example, validated for use in Swahili, a ... study, however, researchers at Brown University and the University ... that they implemented at two sites in the country ...
    (Date:9/30/2014)... passed in 2003 to slow the spiraling costs of ... Medicare patients has had no meaningful impact on cancer ... the Journal of Clinical Oncology published online ... to treat colorectal and lung cancers, and did not ... drugs following the implementation of the recent Medicare law ...
    (Date:9/30/2014)... 2014 Dynamic health trends, changing ... in the Bread Production industry over the past ... moderate their consumption of a variety of industry ... shrunk the market for white loaf bread and ... by introducing more nutritious products to attract health-conscious ...
    (Date:9/30/2014)... (FQHCs) granted new patient appointments to Medicaid beneficiaries ... primary care practices (non-FQHCs), in addition to charging ... new 10-state University of Pennsylvania study published this ... data from a previous "secret shopper" study conducted ... FQHCs community health clinics that receive federal ...
    (Date:9/30/2014)... September 30, 2014(BRONX, NY)Medications are the leading cause of ... analysis of death certificates from 1999 to 2010, conducted ... and Albert Einstein College of Medicine of Yeshiva ... Journal of Allergy and Clinical Immunology , also ... was particularly high among older people and African-Americans and ...
    Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2
    ... Field, IRVING, Texas, Sept. 11 Over 90 ... solicitations during their training,and 80 percent received two dozen ... Merritt, Hawkins & Associates, a national physician,search firm based ... "Like blue chip athletes, new doctors are the ...
    ... 11 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX,: HAE), ... plasma-derived protein products for commercialization,disclosed today the ... on the use of its proprietary lead ... preventing the formation of post-surgical,adhesions in a ...
    ... scoop, NEW YORK, Sept. 11 If ... impact a person,s body and skin, it,s a ... procedures last,year to improve their appearances. However, New ... can improve your appearance,without going under the knife!, ...
    ... will be of great interest to employers and employee benefit brokers ... grounbreaking wellness and health management tool designed to help control costs ... ... (PRWEB) September 11, 2008 -- U.S. Preventive Medicine, the leader in ...
    ... for the medical tourism industry. Working closely with medical tourism ... trip cancellation insurance products to meet the needs of the industry. ... ... Clements International develops unique suite of insurance solutions for the medical ...
    ... a traumatic injury can have serious and long-lasting ... the largest-ever U.S. study evaluating the impact of ... and Research Center, the University of Washington, and ... found that post-traumatic stress disorder and depression were ...
    Cached Medicine News:Health News:Survey: New Doctors Receive Dozens of Job Solicitations 2Health News:Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model 2Health News:Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model 3Health News:Insider Secrets for Beautiful Skin 2Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 2Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 3Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 4Health News:Clements International Develops Insurance for Medical Tourism Industry 2Health News:National study finds post-traumatic stress disorder common among injured patients 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: